CARDIOMETABOLIC BENEFIT BEYOND GLYCEMIC CONTROL FOR T2D: DUAL AGONISM DUEL



WELCOME Dr. Juan Pablo Frias





Copyright © 2022, Medical Le

POLLING RESULTS Dr. Juan Pablo Frias



Meet Mr. Murray

Background

- 52-year-old black male
- Oil rig technician for over 25 years
- Diagnosed with T2D 10 years ago
- Has always struggled to achieve good glycemic control and has had progressive increase in body weight over the past 15 years
- Several family members have recently suffered significant complications of T2D and obesity, and he is motivated to take better care of himself

Social History/Lifestyle

- Married and has 4 grown children that have left the house; non-smoker and rare ETOH
- "No time for healthy eating or exercise due to demands at work.... Often away from home and healthy diet is difficult"
- Excellent health insurance through • employer

Not an actual patient or profile; "Mr. Murray" will be used throughout the presentation.





Mr. Murray's clinical history

Medical History

 T2D, obesity, hypertension, dyslipidemia, sleep apnea, NAFLD, and OA of knees (no known ASCVD)

Physical Exam and Labs

- BP 132/75 mmHg
- Weight 115 kg, BMI 36 kg/m²
- Normal retinal and thyroid exam
- A1c 8.6% (6 months ago 8.4%)
- Lipids: TC 182 mg/dL, LDL-C 108 mg/dL, TG 181 mg/dL, HDL-C 38 mg/dL
- Mildly elevated AST and ALT
- eGFR: 92 mL/min/1.73 m²
- UACR: <30 mg/g

metformin 1000 mg BID, glimepiride 4 mg QD, sitagliptin 100 mg QD

Other Meds/Treatments

losartan 100 mg QD, amlodipine 5 mg QD, chlorthalidone 50 mg QD, atorvastatin 10 mg QD, nightly CPAP





UNMET NEEDS IN T2D Dr. Donna Ryan





Copyright © 2022, Medical

Goals of diabetes care

- Improve cardiometabolic health
- Prevent complications
- Improve health-related quality of life








AN DIABETES ASSOCIATION

STANDARDS OF MEDICAL CARE IN DIABETES-2022




Where do we stand in optimal diabetes care?



Fang M, et al. N Engl J Med. 2021;384:2219-2228.




Twin epidemics of T2D and obesity



Wang L, et al. JAMA. 2021;326:704-716.

https://www.cdc.gov/nchs/products/databriefs/db360.htm#fig4

The obesity and diabetes syndemic



Social environment

Disadvantage

T2D

- Sociocultural barriers
- Income inequality



Moderate weight loss has benefits greater weight loss is associated with greater benefits

-3.0%	 Measures of glycemia¹ Triglycerides and HDL cholesterol¹
-5.0%	 Systolic and diastolic blood pressure¹
-10.0%	 Progression from prediabetes to diabetes Hepatic steatosis (measured by MRS)²
-15.0%	 Measures of feeling and function
-20.0%	 Symptoms of urinary stress incontin Measures of sexual function³
-25.0%	– Quality of life measures (IVVQOL) ²
	 NASH activity score (measured by bid Apnea-hypopnea index¹ Reduction in CV events, mortality, rem

1. Cefalu WT, et al. Diabetes Care. 2015;38:1567-1582; 2. Lazo M, et al. Diabetes Care. 2010;33:2156-2163. 3. Wing R, et al. Diabetes Care. 2013;36:2937-2944; 4. Kolotkin RL, et al. Obes Res. 2001;9:564-571. 5. Sjostrom L, et al. JAMA. 2012;307:56-65; 6. Sjostrom L, et al. JAMA. 2014;311:2297-2304.

-)¹ Detes¹ S)²
- inence¹
- _)4 piopsy)1

mission of T2D^{5,6}



Emergence of new classes of T2D therapeutics

- GLP-1 RAs (2005)
 - Favorable weight loss profiles (liraglutide and semaglutide)
 - CV risk reduction (liraglutide, dulaglutide, semaglutide)
- SGLT2 inhibitors (2015)
 - Favorable weight loss and blood pressure profile
 - CV risk reduction, nephropathy reduction
- Dual GIP/GLP-1R agonist (2022)
 - Novel, once-weekly GIP and GLP-1 dual receptor agonist new class
 - Enhanced glycemic control and weight loss benefits

1. Wing RR. Look AHEAD Research Group. Obesity (Silver Spring). 2021;29:1246-1258.


2. Schauer PR, et al for the STAMPEDE Investigators. N Engl J Med. 2017;376:641-651.

3. Thomas MK, et al. J Clin Endocrinol Metab. 2021;106(2):388-396







Treatment for T2D to minimize weight gain/promote weight loss





Used with permission from: Standards of Medical Care in Diabetes - 2022 Abridged for Primary Care Providers. Clin Diabetes. 2022;40:10-38. doi:10.2337/cd22-as01








Meeting the challenge of weight-centric diabetes management

Glycemic Targets: One Size Does Not Fit All



 Be selective in choosing patients for intensive efforts in weight management, just as in the ADA approach to individualizing glycemic targets

- possible
- techniques


Inzucchi S, et al, **Diabetes Care.** 2012;35:1364-1379.

 Prescribe wisely; choose medications with favorable weight profiles whenever

 Remember to use motivational interviewing and shared decision-making



How to talk to your patients about weight management



Patient communication is key to weight management success

Patients prefer the terms "excess body weight," "BMI," "above ideal body weight," and "maintaining a healthy weight"


They dislike the terms "excess fat," "obese," and "obesity"

Seek the patient's permission to discuss weight

- "As we get your glucose under control, do you have additional goals concerning your weight?"
- "What kind of help from me would you like regarding your weight?"

https://www.niddk.nih.gov/health-information/professionals/clinical-tools-patient-management/weight-management/talking-adult-patients-tips-primary-care-clinicians








DELINEATING THE INCRETIN EFFECT AND THE ROLES OF **GLP-1 AND GIP**

POTENTIAL BENEFITS OF AGONISM OF MULTIPLE **RECEPTORS: MECHANISM OF ACTION OF** UNIMOLECULAR DUAL AGONISTS

Dr. Michael Nauck




The incretin effect in healthy subjects



Used with permission from: Nauck MA, Meier JJ. Lancet Diabetes Endocrinol. 2016;4:525-536.


The incretin effect in type 2 diabetes



Nauck MA, et al. Diabetologia. 1986;29:46-52.



GIP and GLP-1 administered as single agents or in combination in T2D patients



GLP-1 stimulates insulin secretion and reduces plasma glucose, but GIP has no effect




The traditional view

A reduced incretin effect in T2D indicates an inability of GIP to stimulate insulin secretion



Is GIP the obesity hormone?



Intestinal glucose absorption

Insulin release

Storage of fat



The traditional view

GIP receptor stimulation promotes obesity




Recent findings on GIP receptor agonism and body weight in animal studies

GIP receptor stimulation leads to reduced food intake and weight loss





GIP add GLP-1 receptor expression in hypothalamic neurons (eg, arcuate nucleus)




Adriaenssens AE, et al. Cell Metab. 2019;30:987-996.

ARC, arcuate; DMH, dorsomedial hypothalamic; Gip, glucose-dependent insulinotropic polypeptide; Gipr, GIP receptor; Glp1r, glucagon-like peptide-1 receptor




GIP reduces food intake and body weight by interacting with CNS-GIPR






GIP, GLP-1, and their combination reduce food intake and body weight in mice



Intracerebroventricular injection

Effects of exogenous GIP, GLP-1, and their combination on food intake in human subjects




Energy expenditure not changed by any treatment

Intravenous injection

The reduction in energy intake with GLP-1 is confirmed. GIP alone was without effect. The combination with GLP-1 showed a reduced effect.



Bariatric surgery creates a novel pancreatic-intestinal hormonal milieu



Modified from: Nauck MA, et al. Lancet Diabetes Endocrinol. 2021;9:525-544.


PYY, peptide YY


Bariatric surgery creates a gut hormonal milieu associated with weight loss and T2D remission

GIP and GLP-1 (plus additional hormones) together may participate in these effects




The influence of GIP and GLP-1 on postprandial glucose tested by use of specific receptor antagonists in human subjects






Glucose control (intensified regimen) improved insulin and B-cell response to GLP-1 and GIP in patients with T2D




Mean blood glucose before (navy circles) and during (green circles) 4 weeks of insulin treatment. The patients measured blood glucose seven times per day three times per week. Data are mean \pm SEM

Adapted from Højberg P, et al. Diabetologia. 2009;52:199-207.



Tirzepatide: a single molecule stimulating GIP and GLP-1 receptors



Slide courtesy of M Nauck

Amino acid number (relative to native GIP)

CLINICAL IMPLICATIONS OF DUAL AGONIST EFFICACY DATA: GLUCOSE

Dr. Juan Pablo Frias






Advanced engineering: dual GIP/GLP-1 receptor agonist

- Tirzepatide is a multi-functional peptide based on the native GIP peptide sequence, engineered to bind to both GIP and GLP-1 receptors
- 39 amino acid linear peptide and includes a C20 fatty diacid moiety
- Mean half-life of ~5 days (116.7 h), enabling once-weekly dosing
- Plasma concentrations in people with renal and hepatic impairment do not differ from healthy people

Single agent possessing activity at 2 pharmacologic targets


Coskun T, et al. Mol Metab. 2018;18:3-14. Urva S, et al. Diabetes. 2020 (Suppl. 1); abstract 971-P.

GIP, glucose-dependent insulinotropic polypeptide; GLP-1 Ras, glucagon-like peptide-1 receptor agonists





The SURPASS program: clinical trials across the spectrum of **T2D**



1. Rosenstock J, et al. Lancet. 2021;398:143-155. 2. Frías JP, et al. N Engl J Med. 2021;385:503-515. 3. Ludvik B, et al. Lancet. 2021;398:583-598. 4. Del Prato S, et al. Lancet. 2021;398:1811-1824. 5. Dahl D, et al. JAMA. 2022;327:534-545. 6. SURPASS-6. Available at: https://clinicaltrials.gov/ct2/show/NCT04537923. Accessed April 2021. 7. SURPASS-CVOT. Available at: https://clinicaltrials.gov/ct2/show/NCT04255433. Accessed April 2021.

OAM = oral antihyperglycemic medication; SU = sulfonylurea; TID = three times daily

2-4 Drug **Combinations**

Combination With Insulin

SURPASS-4 vs insulin glargine⁴

Add-on to \geq 1 and \leq 3 OAMs (metformin, SGLT-2i, or SU)

SURPASS-5 vs placebo⁵


Both with insulin glargine with or without metformin

SURPASS-6 vs insulin lispro (TID)⁶

Both with insulin glargine with or without metformin (ongoing)




SURPASS trial design: tirzepatide 5, 10, and 15 mg versus active comparator or placebo



1. Rosenstock J et al. Lancet. 2021;398:143-155. 2. Frías JP et al. N Engl J Med. 2021;385:503-515. 3. Ludvik B et al. Lancet. 2021;398:583-598. 4. Del Prato S et al. Lancet. 2021;398:1811-1824. 5. Dahl D et al. JAMA. 2022;327:534-545.

Tirzepatide at all doses significantly reduced A1c versus placebo or active comparators




1. Rosenstock J et al. Lancet. 2021;398:143-155. 2. Frías JP et al. N Engl J Med. 2021;385:503-515. 3. Ludvik B et al. Lancet. 2021;398:583-598.

4. Del Prato S et al. Lancet. 2021;398:1811-1824. 5. Dahl D et al. JAMA. 2022;327:534-545.

Copyright © 2022, Medical Learning Institute Inc


Tirzepatide significantly reduced A1c and more patients achieved A1c targets compared with semaglutide 1 mg



Data are LSM (SE); mITT (efficacy analysis set) ANOVA analysis (week 0) and MMRM analysis (week 40). Arrows indicate when the maintenance dose of tirzepatide 5 mg, 10 mg and 15 mg and semaglutide 1 mg are achieved. *p<0.001 vs. semaglutide 1 mg

Frías JP, et al. N Engl J Med. 2021;385:503-515

Tirzepatide improved self-monitored pre- and postprandial glucose compared with semaglutide 1 mg




Tirzepatide 5 mg

Tirzepatide 15 mg




Tirzepatide improved time in range versus insulin degludec after 52 weeks of treatment



TAR>180 mg/dL \blacksquare TIR 71-180 mg/dL \blacksquare TBR \leq 70 mg/dL

All tirzepatide doses (5, 10, and 15 mg) had greater time in range (70-180 mg/dL) and less time below range (<70 mg/dL) compared with insulin degludec at week 52

Battelino T, et al. Lancet Diabetes Endocrinol. 2022;10:407-417.




CLINICAL IMPLICATIONS OF DUAL AGONIST EFFICACY DATA: WEIGHT AND LIPIDS

Dr. Donna Ryan




Tirzepatide decreased weight (kg and %) more than comparators in SURPASS trials



5. Dahl D, et al. JAMA. 2022;327:534-545.

Copyright © 2022, Medical Learning Institute Inc


Tirzepatide sustained the trajectory of weight change (kg and %) over 40 and 52 w better than comparators (SURPASS 2 and 3)




1.Frias JP, et al. **N Engl J Med**. 2021; 385:503-515. 2.Ludvik B, et al. **Lancet**. 2021;398:583-598.

Efficacy estimand

All doses of tirzepatide resulted in greater mean weight change (kg and %) over 2 years (SURPASS 4)



More participants achieved 10% weight loss with all disease of tirzepatide vs comparators



3. Ludvik B, et al. Lancet. 2021;398:583-598. 4. Del Prato S, et al. Lancet. 2021;398:1811-1824.


5. Dahl D, et al. JAMA. 2022;327:534-545.





Superiority vs placebo or active comparator: p < 0.05; p < 0.001

All doses of tirzepatide generally improved lipid profiles better than semaglutide at 40 weeks (SURPASS-2)




Copyright © 2022, Medical Learning Institute Inc

Up to 60% of participants on tirzepatide achieved composite endpoint compared to 22% on once-weekly semaglutide 1 mg (SURPASS-2)

Prespecified composite endpoint

- Alc ≤6.5%, and
- Weight loss $\geq 10\%$, and
- No Level 2 (<54 mg/dL [3.0 mmol]) or Level 3 (severe) hypoglycemia

32%



Participants achieving composite endpoint



	Mr. Murray
Mr. Murray	 52-year-old black man Oil rig technician for over 25 years Diagnosed with T2D 10 years ago Has struggled to achieve glycemic control and has had progressive increase in b Several family members have recently suffered significant complications of T2D a himself
Medical History	• T2D, obesity, hypertension, dyslipidemia, sleep apnea, NAFLD, and OA of knee
Social History/ Lifestyle	 Married and has 4 grown children that have left the house; non-smoker and rare "No time for healthy eating or exercise due to demands at work Often away for excellent health insurance through employer
Physical Exam & Labs	 BP 132/75 mmHg Weight 115 kg, BMI 36 kg/m² Normal retinal and thyroid exam A1c 8.6% (6 months ago 8.4%) Lipids: TC 182 mg/dL, LDL-C 108 mg/dL, TG 181 mg/dL, HDL-C 38 mg/dL eGFR: 92 mL/min/1.73 m² UACR: <30 mg/g
Current Medications	• T2D - metformin 1000 mg BID, glimepiride 4 mg QD, sitagliptin 100 mg QD
Other Meds/ Treatments	 Losartan 100 mg QD, amlodipine 5 mg QD, chlorthalidone 50 mg QD, atorva

body weight over the past 15 years and obesity, and he is motivated to take better care of

es (no known ASCVD)

e ETOH from home and healthy diet is difficult"

CHLEARNING INSTITUTE

astatin 10 mg QD, nightly CPAP

Back to Mr. Murray

- You discuss all options with the patient. You agree to target 15% weight loss and better glycemic control.
- He attends a group discussion of bariatric surgery but says, "I want to try something less aggressive, first."
- He also agrees to follow your lead on changing his medications and adding medications to promote weight loss.



CLINICAL IMPLICATIONS OF DUAL AGONIST DATA: SAFETY, TOLERABILITY, AND CV EFFECTS

Dr. Juan Pablo Frias



Tirzepatide safety and tolerability


- Side effect profile similar to that of selective GLP-1 receptor agonists
- Most common adverse events were gastrointestinal in nature and occurred primarily during dose escalation period

Preferred Term, %	TZP 5 mg (N=470)	TZP 10 mg (N=469)	TZP 15 mg (N=470)	Sema 1 mg (N=469)
Any GI TEAE	40.0	46.1	44.9	41.2
Nausea	17.4	19.2	22.1	17.9
Diarrhea	13.2	16.4	13.8	11.5
Vomiting	5.7	8.5	9.8	8.3
Dyspepsia	7.2	6.2	9.1	6.6
Constipation	6.8	4.5	4.5	5.8
Abdominal pain	3.0	4.5	5.1	5.1

Frías JP, et al. N Engl J Med. 2021;385:503-515.

eceptor agonists n nature and occurred

Incidence of nausea over time through 40 weeks (SURPASS-2)



Most cases of nausea were mild to moderate, transient, and occurred during the dose-escalation period in all groups

Frías JP, et al. N Engl J Med. 2021;385:503-515.

Low incidence of hypoglycemia in SURPASS trials

		TZP 5 mg	TZP 10 mg	TZP 15 mg	Placebo
SURPASS-1 (40 weeks)		(N=121)	(N=119)	(N=120)	(N=115)
Monotherapy	Hypoglycemia*	0	0	0	0.9
	Severe hypoglycemia	0	0	0	0
		TZP 5 mg	TZP 10 mg	TZP 15 mg	Semaglutide
SURPASS-2 (40 weeks)		(N=470)	(N=469)	(N=470)	(N=469)
Metformin	Hypoglycemia*	0.9	0.2	1.7	0.4
	Severe hypoglycemia	0.21	0	0.21	0
		TZP 5 mg	TZP 10 mg	TZP 15 mg	Degludec
SURPASS-3 (52 weeks)		(N=356)	(N=360)	(N=359)	(N=358)
Metformin ± SGLT-2i	Hypoglycemia*	1.4	1.1	2.2	7.3
	Severe hypoglycemia	0	0	0.28	0
		TZP 5 mg	TZP 10 mg	TZP 15 mg	Glargine
SURPASS-4 (52 weeks)		(N=329)	(N=328)	(N=338)	(N=1,000)
\pm Metformin \pm SU \pm SGLT-2i	Hypoglycemia*	8.8	6.1	8.0	19.1
	Severe hypoglycemia	0.30	0	0.89	1.10
		TZP 5 mg	TZP 10 mg	TZP 15 mg	Placebo
SURPASS-5 (40 weeks)		(N=116)	(N=119)	(N=120)	(N=120)
Basal insulin ± Metformin	Hypoglycemia*	15.5	19.3	14.2	12.5
	Severe hypoglycemia	0	1.68	0.83	0

1. Rosenstock J, et al. Lancet. 2021;398:143-155. 2. Frías JP, et al. N Engl J Med. 2021;385:503-515. 3. Ludvik B, et al. Lancet. 2021;398:583-598. 4. Del Prato S, et al. Lancet. 2021;398:1811-1824. 5. Dahl D, et al. JAMA. 2022;327:534-545.

Other adverse events of special interest


Parameters	SURPASS-11	SURPASS-2 ²	SURPASS-3 ³	SURPASS-4 ⁴	SURPASS-5⁵
Pancreatitis ³	0	2 (TZP 10 mg) 2 (TZP 15 mg) 3 (SEMA 1 mg)	0	3 (TZP 5mg) 2 (TZP 10 mg) 1 (TZP 15 mg) 1 (Insulin Glargine)	0
Cholelithiasis	1 (TZP 5 mg)	4 (TZP 5 mg) 4 (TZP 10 mg) 4 (TZP 15mg) 2 (SEMA 1 mg)	2 (TZP 5mg) 1 (TZP 10 mg) 1 (TZP 15 mg)	3 (TZP 5mg) 1 (TZP 10 mg) 1 (TZP 15 mg) 4 (Insulin Glargine)	1 (TZP 5 mg)
Medullary Thyroid Carcinoma	0	0	0	0	N/A*
Diabetic Retinopathy	0	2 (TZP 10 mg)	2 (TZP 5 mg) 1 (TZP 15 mg)	2 (TZP 5mg) 1 (TZP 10 mg) 1 (TZP 15 mg) 1 (Insulin Glargine)	N/A*

1. Rosenstock J, et al. Lancet. 2021;398:143-155. 2. Frías JP, et al. N Engl J Med. 2021;385:503-515. 3. Ludvik B, et al. Lancet. 2021;398:583-598. 4. Del Prato S, et al. Lancet. 2021;398:1811-1824. 5. Dahl D, et al. JAMA. 2022;327:534-545.





Pooled tirzepatide vs pooled comparator effect on time to first MACE-41



1. Sattar N, et al. Nat Med. 2022;28:591–598. 2. https://clinicaltrials.gov/ct2/show/record/NCT04255433

	Mr. Murray
Mr. Murray	 52-year-old black man Oil rig technician for over 25 years Diagnosed with T2D 10 years ago Has struggled to achieve glycemic control and has had progressive increase in b Several family members have recently suffered significant complications of T2D a himself
Medical History	• T2D, obesity, hypertension, dyslipidemia, sleep apnea, NAFLD, and OA of knee
Social History/ Lifestyle	 Married and has 4 grown children that have left the house; non-smoker and rare "No time for healthy eating or exercise due to demands at work Often away for excellent health insurance through employer
Physical Exam & Labs	 BP 132/75 mmHg Weight 115 kg, BMI 36 kg/m² Normal retinal and thyroid exam A1c 8.6% (6 months ago 8.4%) Lipids: TC 182 mg/dL, LDL-C 108 mg/dL, TG 181 mg/dL, HDL-C 38 mg/dL eGFR: 92 mL/min/1.73 m² UACR: <30 mg/g
Current Medications	• T2D - metformin 1000 mg BID, glimepiride 4 mg QD, sitagliptin 100 mg QD
Other Meds/ Treatments	 Losartan 100 mg QD, amlodipine 5 mg QD, chlorthalidone 50 mg QD, atorva

body weight over the past 15 years and obesity, and he is motivated to take better care of

es (no known ASCVD)

e ETOH from home and healthy diet is difficult"

CALLEARNING INSTITUTE.

astatin 10 mg QD, nightly CPAP

Reflection: What do you consider the most important goal(s) and action(s) for the management of Mr. Murray?

- 1. Better glycemic and lipid control. We need to add a thiazolidinedione and intensify lipid-lowering therapy.
- 2. Better glycemic, lipid, and weight control. We need to stop the glimepiride and add tirzepatide. Intensify lipid-lowering therapy and consider adding a SGLT2i.
- 3. Better glycemic, lipid, and weight control. We need to intensify lipid-lowering therapy and refer for bariatric surgery.
- 4. Better glycemic, lipid, and weight control. We need to stop the glimepiride and add a GLP-1 RA with a good CV risk and weight loss profile and consider adding an SGLT2i.



Tirzepatide: key prescribing information and instructions for USE

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D

- Single-dose prefilled pen
- 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL
- The recommended starting dosage is 2.5 mg SC once weekly
- After 4 weeks, increase to 5 mg SC once weekly
- If additional glycemic control is needed, increase the dosage in 2.5-mg increments • after at least 4 weeks on the current dose
- The maximum dosage is 15 mg SC once weekly
- Administer once weekly at any time of day, with or without meals •
- Inject SC in the abdomen, thigh, or upper arm; rotate injection sites with each dose



Tirzepatide: key prescribing information and instructions for use

Contraindications

- Personal or family history of MTC or patients with MEN2
- Known serious hypersensitivity to tirzepatide or any of the excipients

Limitations of Use

- Has not been studied in patients with a history of pancreatitis
- Is not indicated for use in patients with type 1 diabetes

Warnings and Precautions

- **Pancreatitis**
- Hypoglycemia with concomitant use of insulin secretagogues or insulin
- Hypersensitivity reactions
- Acute kidney injury
- Severe gastrointestinal disease
- Diabetic retinopathy complications in patient with a history of diabetic retinopathy
- Acute gallbladder disease




PREVIEWS OF COMING ATTRACTIONS: DUAL AND TRIPLE AGONISTS IN DEVELOPMENT

Dr. Juan Pablo Frias



Tirzepatide development program includes weight loss, NASH, and HF trials



Peptide-based multi-agonists: a new paradigm in metabolic pharmacology





Figure from Brandt SJ, et al. J Intern Med. 2018;284:581-602.

- Cotadutide (MEDI0382)¹
- Pemvidutide (ALT-801)²
- Tirzepatide
- CT-868³ and CT-388⁴
- OW semaglutide + OW NNC0480-0389⁵
- HM152116
- LY3437943⁷

- 1. Robertson D, et al. Diabetes. 2020;69(Supplement_1):951-P.
- 2. https://adisinsight.springer.com/drugs/800037378
- 3. https://clinicaltrials.gov/ct2/show/NCT05110846
- 4. https://clinicaltrials.gov/ct2/show/NCT04838405
- 5. https://trialbulletin.com/lib/trials/term=Coformulation+NNC0480+0389+Semaglutide+A+10+1+mg+mL
- 6. https://clinicaltrials.gov/ct2/show/NCT04505436
- 7. https://clinicaltrials.gov/ct2/show/NCT04881760

Long-acting amylin analog + long-acting GLP-1 RA for the management of obesity and T2D

- Phase 1b, randomized, placebocontrolled, multiple-ascending dose study
- Otherwise healthy volunteers with overweight or obesity (BMI 27.0 39.9 kg/m²)
- Cagrilintide plus semaglutide vs placebo plus semaglutide
- 20-week treatment period



Used with permission from: Enebo LB, et al. Lancet. 2021;397:1736-1748.

TAKE HOME MESSAGES

Dr. Juan Pablo Frias Dr. Donna Ryan Dr. Michael Nauck



